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Introduction
Psoriasis is an immune-mediated disease of skin and
joints often precipitated by infection. Cutaneous
involvement is always the predominant feature. How-
ever, a couple of reports suggest that there might be
also a connection between psoriasis and other organ
disorders, including that of the digestive system [1].
A relationship between Helicobacter pylori infec-
tion and skin disease, especially chronic urticaria, have
been documented. Helicobacter pylori eradication
appears to be beneficial in patients with lichen planus,
prurigo, Sjögren's syndrome, Henoch-Schönlein purpu-
ra, and rosacea [2,3]. Moreover, there are hypotheses
implicating the pathogen in triggering psoriasis [3].
There are also data concerning concurrent presentation
of psoriasis and gastritis, duodenitis, celiac disease or
inflammatory bowel disease [4-6]. A few authors have
related psoriasis and disturbances of the incretory and
excretory pancreatic functions and even acute pancre-
atitis [7-9]. Single reports on liver dysfunction or chron-
ic liver disease in psoriatic individuals have been pub-
lished, including hepatic cirrhosis or psoriasis being a
cutaneous sign of hepatocellular carcinoma [10-14].
Disposition to psoriasis is primarily genetic, but
some dysmetabolic changes, such as obesity, dyslipi-
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Case report
daemia, hyperuricaemia, impaired glucose tolerance or
insulin resistance, may increase the risk for psoriasis
as well as for some of the digestive system disorders,
especially liver diseases [10-11]. On the other hand,
pro-inflammatory factors upregulated in psoriasis,
especially interleukin (IL) 18, are likely to increase
risk of the metabolic syndrome [15]. Previous reports
have endorsed an association between psoriasis and
the metabolic syndrome or lipid abnormalities
[6,16,17]. Furthermore, psoriasis is believed to be an
independent risk factor for subclinical atherosclerosis
[6]. At present the lipid profile, lipoprotein,
apolipoprotein, brain (B-type) natriuretic peptide (BNP)
and its metabolite, N-terminal pro-B-type natriuretic
peptide (NT-proBNP), levels are considered to be good
predictors of cardiovascular disease and may be useful
markers of cardiovascular risk in psoriatics [6,18].
The association between psoriasis and digestive
system disorders remains unclear. The current report
present a case of psoriasis associated with multiple
digestive system disorders and review the literature
regarding the topic.
Case presentation
A 40-year-old man presented with signs and symptoms
consistent with severe and disseminated exudative pso-
riasis. The patient had been diagnosed as having psori-
asis at 8 years of age, and for 32 years he had been pre-
senting with only few small skin plaques with no need
for systemic treatment or hospitalisation. Approximate-
ly 6 months preceding admission he suddenly devel-
oped a severe exacerbation of the disease. He was treat-
ed with various topical corticosteroid preparations,
such as fluticasone, clobetasol or betamethasone with
salicylic acid ointments (subsequently), and short-term
oral doxycycline (2×100 mg/d; 10 days) and niacin
(3×200 mg/d). However, the treatment proved ineffec-
tive and his skin condition gradually worsened, espe-
cially following a flu-like illness 2-3 weeks prior to the
admission. On admission the patient suffered from
intense pruritus within the involved skin and malaise.
He made no other complaints; he denied any prior or
current gastrointestinal symptoms. His medical history
included hypertension for more than 3 years, and his
daily medication consisted of perindopril (1×5 mg/d).
However, due to normal blood pressure values (mean
135/70 mmHg) for more than 2 months, the antihyper-
tensive drug had been withdrawn. The patient did not
have any history of blood transfusion or habitual alco-
hol consumption, and had not ingested alcohol or any
drugs known to induce pancreatitis or liver damage
prior to the admission. There was substantial tobacco
consumption habit, up to 30 cigarettes per day. A fam-
ily history of psoriasis was apparent; the patient's
mother suffered from the disease since childhood. Of
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Fig. 1. Patient's lower extremities before (a) and after 2 weeks of treatment (b,c). Detailed description in text.
note, the patient had neither familial nor personal his-
tory of gastrointestinal disorders.
On the admission psoriatic lesions covered approx-
imately 40% of the cutaneous surface, including the
scalp, trunk, buttocks, and upper and lower extremi-
ties, but not the face, neck, palms and soles. There
were a large number of patches, ranging in size from 1
to 10 cm in diameter and having a tendency to conflu-
ence. The most prominent lesions were present on the
right shin, involving the entire anterior and lateral
aspect of the limb. They were very distinctive, full red
colour with a violaceous tint and covered with fine
scales (Fig. 1a). The psoriatic plaques on medial aspect
of the left shin, as well as the lesions on medial sur-
faces of both arms and forearms displayed the trend to
coalesce into large patches, up to man's hand size.
Small water drop-shaped or coin-shaped plaques up to
large patches covered with medium scales were
observed on the other involved areas. The thighs were
the exception with the lesions inflamed, thick and mul-
tilayered associated with overlapping scales resem-
bling rupees. The PASI score was estimated at 28.7.
Physical examination demonstrated overweight, body
mass index was calculated at 29.76 kg/m2. There was
no evidence of any bacterial or viral infection.
Laboratory data (Table 1) revealed a remarkable
elevation of serum lipase and amylase activity and
abnormal liver function tests. The levels of total cho-
lesterol and LDL cholesterol were slightly increased,
whereas the serum concentrations of triglyceride and
HDL cholesterol were within normal range. More
detailed analysis disclosed abnormal ApoB/ApoA-I
ratio. In addition, there were significant increases in
serum level of CRP (C reactive protein) and
NT-proBNP. All virologic and serologic markers for
hepatitis B and C virus were negative. An abdominal
ultrasound revealed slight hepatomegaly and inhomo-
geneous fatty change of the liver (Fig. 2). No stones or
sludge of the gallbladder and of the common bile duct
were detected. The pancreas was homogeneous and
measured 25 mm at the head, 26 mm at the body, and
29 mm at the tail. An upper gastrointestinal tract
endoscopy displayed no macroscopic pathology of the
oesophagus, stomach or duodenum. H. pylori infection
was diagnosed with a biopsy check during endoscopy
with a rapid urease test. Histological examination of
gastric and duodenal mucosa biopsies disclosed signif-
icant inflammatory changes (Fig. 3). Despite remark-
able disturbances of serum lipid profile, there were no
significant abnormalities on cardiological examina-
tion. The transthoracic echocardiography revealed
only negligible dilatation of the left atrium and ventri-
cle and slight left ventricle hypertrophy, but there were
no changes of the left ventricle ejection fraction.
Initially topical treatment for psoriasis consisted of
dexpanthenol aerosol. Subsequently it was continued
with corticosteroid preparations, including hydrocorti-
sone ointment, betamethasone with salicylic acid oint-
ment and then fluticasone cream, combined with
0.125-0.25% cignolin, cholesterol, urea with salicylic
acid, salicylic acid sulfur soap, or sulfur salicylic acid
ointments. In addition, oral antihistamine therapy with
clemastine (2×1 mg/d) for 10 days and subsequently
with fexofenadine (1×180 mg/d) was introduced.
Therapeutic measures for gastrointestinal disorders
included appropriate diet and pancrelipase (10,000 IU
per meal or snack; 3×/d), as well as hepatoprotectants,
such as thiazolidine-4-carboxylic acid (3×200 mg/d)
and essential phospholipids, especially 3-sn-phos-
phatidylcholine (2×300 mg/d). The patient received
vitamin E (3×100 mg/d), and ascorbic acid combined
with rutoside (3×200+50 mg/d) as well. Moreover,
with the H. pylori infection diagnosis the standard
treatment for the pathogen eradication was initiated,
consisting of amoxycillin (2×1 g/d; 10 days) and clar-
ithromycin (2×500 mg/d; 14 days) combined with
omeprazole (2×20 mg/d; 14 days). Within 2 weeks of
the treatment a considerable clinical improvement was
achieved. The itching subsided. The skin lesions start-
ed to remit gradually. At the time of discharge psoriat-
ic scales persisted only on the skin of knee-joints and
right shin, at the other sites previously covered with
lesions there were distinct post-inflammatory hyper-
pigmentations (Fig. 1b, c). Simultaneously trend to
normalisation of the pancreas and liver function
parameters was observed (Table 1).
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Fig. 2. Liver ultrasound scan. Inhomogeneous increase of the liver
echogenicity within the segment 4 of the right lobe (arrowheads), the
segment 7 of the right lobe and the segments 2 and 3 of the left lobe.
Hepatomegaly; the liver size in the anterior axial line was 146 mm;
in the midclavicular line, 119 mm; and in the sternal line, 84 mm.
Discussion
Little is known about the potential relationship
between psoriasis and gastrointestinal, pancreas and
liver dysfunction. However, the digestive system dis-
orders are speculated to be involved in the psoriasis
pathology. The presented case, consistently with a few
published reports, appears to suggest that H. pylori
infection may be related to psoriasis. Nevertheless, the
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Table 1. Clinical characteristic of the patient (normal reference ranges are given in parentheses; * for individuals younger than 75 years).
ALT – alanine transferase; ApoA-I – apolipoprotein A-I; ApoB – apolipoprotein B; AST – aspartate transferase; CRP – C reactive protein; γ-GTP – γ-glu-
tamyl transpeptidase; HBs-Ag – hepatitis B surface antigen; HCV-Ab – hepatitis C virus antibody; HDL – high density lipoprotein; IU/L – international
units/liter; LDL – low density lipoprotein; MCV – mean corpuscular volume (i.e. average red blood cell size); NT-proBNP – N-terminal pro B-type natri-
uretic peptide; PASI – Psoriasis Area and Severity Index.
existing literature data are conflicting. Some authors
described marked improvement and/or remission of
the refractory disease following proven bacteria eradi-
cation [19,20], whereas others consider the approach
to be of no benefit to psoriatic individuals [21]. For
example, Dauden et al. [21] observed no improvement
of psoriatic lesions, despite successful H. pylori eradi-
cation. Potential cutaneous pathology of H. pylori
remains unknown, but it may be associated with a
superantigen effect of the bacteria or their products,
increased mucosal permeability of the gastrointestinal
tract, various autoimmune mechanisms, or impairment
of vascular integrity [2]. Recently, a hypothesis of
superantigen-mediated pathogenicity has became a
focus for research on psoriasis [22]. This new concept
of psoriasis pathophysiology, defining it as a 
Th-1-mediated disorder, implicates superantigens in
triggering the disease. As they bind MHC class-II mol-
ecules, not only constitutively expressed HLA-DR
molecules on professional antigen-presenting cells,
including macrophages and dendritic cells, but also
cytokine-induced HLA-DR molecules on nonprofes-
sional antigen-presenting cells, such as keratinocytes,
without any prior processing, superantigens easily
prime large number of resting T cells. Superantigen-
induced T cells are likely to produce large amounts of
inflammatory cytokines, including TNF-α and -β, IL-2
or INF-γ [2,22]. It is enticing to speculate that some of
unique virulence factors developed by H. pylori to sur-
vive and proliferate in the stomach may act as super-
antigens (i.e. immunostimulatory molecules acting as
Vβ-restricted extremely potent polyclonal T cell mito-
gens). These may include the urease, flagellar proteins,
an H-gated urea transporter, several adhesins, and espe-
cially multifunctional vacuolating cytotoxin A (VacA)
and the cytotoxin-associated gene pathogenicity island
(cag-PAI). Of note, expression of the cag-PAI is
responsible for the building of a secretion apparatus
delivering some bacterial proteins, such as an immun-
odominant antigen cag A, directly into the cytosol of
host cells [2,23]. However, preliminary study of Dau-
den et al. [23] indicated that cag A status was not asso-
ciated with type, severity and duration of psoriasis.
Another factor probably linking H. pylori infection
and the psoriasis pathophysiology is increased mucos-
al permeability of the stomach and intestine. Abnor-
malities of gastric or intestinal epithelium structure
and function might result in a greater exposure to ali-
mentary antigens or toxins, including microbial fac-
tors. These may leak into circulation, evoke specific
immune response and eventually may be deposited
along the skin basement membrane zone, which is
believed to be the first step of their percutaneous elim-
ination. If microbial antigens share structural homolo-
gies with skin components (molecular mimicry), the
additional result may be the development of antigen-
antibody complexes, cross-reactive antibodies or spe-
cific T cells cross-reacting against epidermal autoanti-
gens [24,25]. For example, molecular mimicry
between H. pylori antigens and keratin 17 may result
in activation of autoreactive T cells and augment ker-
atinocyte hyperproliferation [22]. Moreover, some 
H. pylori products or structural proteins may cross-
react with such extragastrointestinal epitopes as Lewis
antigens [26,27], sialylated glycoconjugates [28] or
sialic residues of laminin [29]. Humbert et al. [30]
findings seem to support the hypothesis. Increased
mucosal permeability of the stomach and intestine has
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Fig. 3. Histological examination of gastric (a) and duodenal (b) biopsies (H+E). (a) Gastric mucosa with hyperaemia, oedema and mod-
erate infiltration with plasma cells and lymphocytes as well as single eosinophils and neutrophils (original magnification, ×20). (b) Duo-
denal mucosa with considerable hyperaemia and oedema, most prominent within stroma of the duodenal papilla. Moreover, there is mod-
erately increased cellularity of the mucosa with lymphocytes and plasma cells, and single neutrophils and eosinophils (original magnifi-
cation, ×40). The histopathological examination is consistent with persistent gastritis and duodenitis, respectively.
been demonstrated in H. pylori-infected subjects as
well [31]. Vascular impairment is considered to be
another important component of the most skin diseases
linked to H. pylori infection. Animal studies demon-
strated that the bacteria disrupted interstitial and
intravascular cell to cell interactions, leading to
marked microvascular dysfunction [32]. Furthermore,
it is probably associated with increased levels of fib-
rinogen [33], and platelet activation and aggregation
[34], other processes implicated in the microvascular
dysfunction and inflammatory-cell recruitment.
Presented medical history may also signal the rela-
tionship between psoriasis and pancreas disorders.
Intriguingly, no clinical signs or symptoms of pancre-
atitis were reported; especially the patient denied
abdominal pain, which is a dominant feature of the dis-
ease. Literature data indicate that asymptomatic abnor-
malities of pancreatic enzymes are not infrequent in
patients with inflammatory bowel diseases, or positive
for chronic hepatitis B or C virus, or HIV infection.
Most of these patients do not develop clinical pancre-
atitis and usually do not require specific therapy
[35,36]. Only few reports regarding the pancreas dys-
function in psoriasis have been published [7,8].
Pietrzak et al. [7] demonstrated higher serum levels of
pancreatic lipase in male psoriatics compared to
healthy controls. Khardikova et al. [8] observed
impaired exocrine and endocrine pancreas function in
psoriatic individuals, the latter finding may account for
higher prevalence of diabetes mellitus in psoriasis
[37]. Recently recurrent acute pancreatitis over the
course of psoriatic arthritis has been described [9]. In
the case presented here interpretation may be biased by
the patient's hypertension history and perindopril
administration. One should remember that some sys-
temic as well as topical medications were sporadically
linked to acute pancreatitis [38-41] including
angiotensin-converting enzyme inhibitors (i.e. perindo-
pril) [42,43]. However, the patient had not presented
with any signs and symptoms within prior three-year
antihypertensive treatment, and due to normal blood
pressure values, he had not been taking the compound
for more than 2 months preceding the diagnosis of pan-
creatitis. Other pancreatitis causes, including mechani-
cal obstacle or current heavy drinking, were excluded
with the use of various gold-standard techniques. Pos-
sible relationship between psoriasis and pancreatitis
remains an enigma. A noteworthy hypothesis could be
that of intestinal barrier dysfunction, all the more since
some authors reported increased intestinal permeability
in patients with acute pancreatitis [44,45]. There is,
however, another possibility. Some clinical and experi-
mental evidence suggests that the immune system and
pro-inflammatory cytokines play a key role in the
pathogenesis of acute pancreatitis, with IL-18 being
one of the pivotal mediators of inflammation [46]. One
should appreciate that IL-18 is believed to be involved
in psoriasis development and is up-regulated in psoriat-
ic individuals [47,48].
At the end of the list of digestive system pathology
observed in the presented case, but not least, are liver
abnormalities. The literature analysis revealed a cou-
ple of reports of recurrent cholestatic jaundice related
to generalised pustular psoriasis. The jaundice
episodes were of unclear pathogenesis, but some neu-
trophilic cholangitis was documented on liver biopsy.
It raised the question whether the organ was the sub-
ject to the same disorder as the skin, inasmuch accu-
mulation of neutrophils in the epidermis is one of the
vital histological features of pustular psoriasis [12,13].
Apart from biliary involvement in the course of pustu-
lar psoriasis, nonalcoholic steatohepatitis was linked to
psoriasis vulgaris [10,11]. The fatty liver change relat-
ed to psoriasis vulgaris were noted in the
"POLI.ST.E.N.A." study, being a prospective survey
on the nonalcoholic fatty liver disease (NAFLD) [10].
The conditions coexisted in overweight or obese
young adults with a central-type body fat distribution.
Of note, not only is obesity believed to be associated
with NAFLD, but also it has been reported to be a sep-
arate risk factor for more severe psoriasis [6,49,50].
Given the current trends in systemic therapy of psoria-
sis, especially the usage of drugs of well documented
hepatotoxicity, e.g. methotrexate, the association of
the disease and even modest liver damage might be of
great clinical importance [51]. The pathogenetic link
between psoriasis, obesity and NAFLD remains
unclear. However, evolving research suggests that the
chronic inflammatory nature of psoriasis itself may be
an important factor for the mentioned relationships.
Psoriasis is characterised by a Th1 cytokine prepon-
derance, and these factors have pleiotropic effects on a
large variety of processes, including angiogenesis,
insulin signalling, adipogenesis, lipid metabolism,
immune cell trafficking, or epidermal proliferation.
Therefore, pro-inflammatory cytokines (e.g. TNF, 
IL-6, IL-18) are not only implicated in the psoriasis
pathogenesis, but might cause inflammation in other
organs as well [15]. For example, IL-18 was signifi-
cantly upregulated in subjects with NAFLD and
according to Vecchiet et al. [52] the factor might be
even an important marker of liver diseases. In turn
enhanced expression of TNF and IL-6 has been detect-
ed in the adipose tissue, which may implicate it in the
local and systemic inflammatory responses [53].
The association between psoriasis and the metabol-
ic syndrome gives rise to particular concern, due to a
possible increase of cardiovascular risk. Indeed epi-
demiological studies revealed high prevalence of car-
diovascular co-morbidity among psoriatic patients
[6,54]. Refractory dyslipidaemia and other lipid pro-
file abnormalities, especially abnormal ApoB/ApoA-I
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ratio and NT-proBNP level (heart failure marker),
observed in the presented case seem to confirm
described relationships and may signal the very onset
of atherosclerotic vascular disease. The root cause of
NT-proBNP level increase in the current case is
unclear, but it may indicate the presence of cardiac
dysfunction, in spite of insignificant cardiac examina-
tion. Of course, one should not overlook potential con-
founding factors that might significantly contribute to
NT-proBNP elevation, including smoking, hyperc-
holestrolaemia or drugs (e.g. angiotensin-converting
enzyme inhibitors). Importantly, literature data
demonstrated unchanged hepatic degradation of 
NT-proBNP in cirrhosis and no correlation was found
between the marker levels and the hyperdynamic cir-
culatory changes in cirrhotic subjects [55]. On the
other hand, the levels of BNP and NT-proBNP tend to
be lower in obese people, and hepatic steatosis is
rather associated with low levels of NT-proBNP
[56,57].
The findings of this case seem to suggest some kind
of interplay between psoriasis and digestive system
disorders. Further studies are needed to establish if the
pathogenic links exists and elucidate a possible chain
of cause and effect as well as time relationships
between specific disorders.
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